|
 |
 |
 |
 |
 |
 |
- Home
- Join or Change Subscription
- GSI Community
- For New Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
 | |
 | |
Sorafenib tosylate (brand name Nexavar)
Sorafenib (formerly called BAY 43-9006, now brand-named Nexavar) is an oral multikinase inhibitor that blocks the RAF kinase and VEGF receptors 2 and 3 to target tumor cell growth and angiogenesis, as well as PDGFR-B, KIT, FLT-3, and RET. During 2005 it was in clinical trials for kidney cancer and melanoma. Nexavar was approved by the FDA for use against kidney cancer in December 2005.
A GIST trial for sorafenib began in January 2006 at the University of Chicago under the direction of Dr. Hedy Kindler, principal investigator. The title is “A Phase II Study of BAY 43-9006 for Patients with Imatinib-Resistant Malignant Gastrointestinal Stromal Tumor.” The contact person for the trial is Karen Wendling, phone 773-834-7424. The trial has expanded to Memorial Sloan Kettering Cancer Center and will be offered at other treatment centers after the trial progresses. For trial information link to: clinicaltrials.gov or cancer.gov
The first report about this trial was presented at the January 2008 ASCO GI Cancers Symposium, where a paper reported some positive results in GIST patients who had previously experienced progression either on imatinib or on both imatinib and sunitinib. Link below for the abstract of this paper and associated slides:
Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
Authors: H. S. Nimeiri, R. G. Maki, K. Kasza, D. D'Adamo, W. Chow, P. Dy, B. Polite, J. Jin, E. E. Vokes, H. L. Kindler
Development of sorafenib (Nexavar) is co-sponsored by two different pharmaceutical firms: Bayer and Onyx.
LINKS to relevant information:
- http://www.nexavar.com
- manufacturer information about this drug
- More about BAY 43-9009 clinical trials pertaining to GIST
- Medical papers pertaining to this drug (not with respect to GIST)
- 2004 powerpoint presentation about this drug by Dr. Eisen.
